Latest News & Updates
Breaking News
2 hours ago
Pharma Now Editorial Team
Sanofi Gains FDA Priority Review for Venglustat in Gaucher Disease Type 3
Pharma Now Editorial Team
Novo Nordisk Presents Late-Stage Pipeline and Semaglutide Expansion Data at ADA 2026
Pharma Now Editorial Team
Other trending news you may like to read
Anaveon Achieves Phase 1 Clinical Benefit Signal for ANV600 as Company Seeks Oncology Partners
Anaveon presents EXPAND-1 Phase 1 data for ANV600 at ASCO 2026, reporting 42% disease control in monotherapy, as the company seeks global oncology partners.
Pharma Now Editorial Team
Lupin Gains FDA Establishment Inspection Report for Ankleshwar Facility Following Pre-Approval Inspection Closure
Lupin's Ankleshwar site receives FDA EIR after a product-specific pre-approval inspection in March 2026, clearing a key compliance checkpoint.
Pharma Now Editorial Team
Sanofi Gains FDA Priority Review for Venglustat in Gaucher Disease Type 3
FDA grants Priority Review to Sanofi's venglustat NDA for Gaucher disease type 3, with a PDUFA date of 25 November 2026.
Pharma Now Editorial Team
Novo Nordisk Presents Late-Stage Pipeline and Semaglutide Expansion Data at ADA 2026
Novo Nordisk's ADA 2026 data across semaglutide and GLP-1 pipeline programs signals near-term API and CDMO demand shifts.
Pharma Now Editorial Team
